AU2020347536B2 - Rifabutin treatment methods, uses, and compositions - Google Patents

Rifabutin treatment methods, uses, and compositions

Info

Publication number
AU2020347536B2
AU2020347536B2 AU2020347536A AU2020347536A AU2020347536B2 AU 2020347536 B2 AU2020347536 B2 AU 2020347536B2 AU 2020347536 A AU2020347536 A AU 2020347536A AU 2020347536 A AU2020347536 A AU 2020347536A AU 2020347536 B2 AU2020347536 B2 AU 2020347536B2
Authority
AU
Australia
Prior art keywords
rifabutin
baumannii
fhue
cmax
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020347536A
Other languages
English (en)
Other versions
AU2020347536A1 (en
Inventor
Glenn E. Dale
Marc Gitzinger
Christian Kemmer
Sergio Lociuro
Vincent Trebosc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioversys AG
Original Assignee
Bioversys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioversys AG filed Critical Bioversys AG
Publication of AU2020347536A1 publication Critical patent/AU2020347536A1/en
Application granted granted Critical
Publication of AU2020347536B2 publication Critical patent/AU2020347536B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020347536A 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions Active AU2020347536B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US62/899,257 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US62/902,019 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US62/941,160 2019-11-27
US202062977659P 2020-02-17 2020-02-17
US62/977,659 2020-02-17
PCT/IB2020/000647 WO2021048611A1 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions

Publications (2)

Publication Number Publication Date
AU2020347536A1 AU2020347536A1 (en) 2022-04-14
AU2020347536B2 true AU2020347536B2 (en) 2025-09-25

Family

ID=72432957

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020347536A Active AU2020347536B2 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions
AU2020344214A Active AU2020344214B2 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020344214A Active AU2020344214B2 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Country Status (17)

Country Link
US (6) US11351158B2 (cg-RX-API-DMAC7.html)
EP (3) EP4028001B1 (cg-RX-API-DMAC7.html)
JP (4) JP7804570B2 (cg-RX-API-DMAC7.html)
KR (1) KR102991225B1 (cg-RX-API-DMAC7.html)
CN (3) CN115052597B (cg-RX-API-DMAC7.html)
AU (2) AU2020347536B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022004645A2 (cg-RX-API-DMAC7.html)
CA (2) CA3154317A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982067T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240818T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066936T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022003077A (cg-RX-API-DMAC7.html)
PH (1) PH12022550610A1 (cg-RX-API-DMAC7.html)
PL (1) PL4028001T3 (cg-RX-API-DMAC7.html)
RS (1) RS65681B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400250T1 (cg-RX-API-DMAC7.html)
WO (2) WO2021048610A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106364A1 (en) * 2011-01-31 2012-08-09 The Government Of The United States, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
US20190269806A1 (en) * 2017-02-07 2019-09-05 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN101362067A (zh) * 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
PL2247291T3 (pl) * 2008-02-08 2019-05-31 Red Hill Biopharma Ltd Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit
MY158809A (en) 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
CN102178604B (zh) 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
RU2472512C1 (ru) * 2011-12-06 2013-01-20 Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" Противотуберкулезная композиция и способ ее получения
US10953070B2 (en) * 2014-07-25 2021-03-23 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
EP3189154B1 (en) * 2014-09-04 2023-03-22 Labrador Diagnostics LLC Pathogen and antimicrobial resistance testing
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
CN109789125B (zh) * 2016-08-16 2022-10-18 罗切斯特大学 含有基于多粘菌素b/甲氧苄啶的治疗剂的药物组合物
US11701346B2 (en) 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii
US20230364065A1 (en) * 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106364A1 (en) * 2011-01-31 2012-08-09 The Government Of The United States, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
US20190269806A1 (en) * 2017-02-07 2019-09-05 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction

Also Published As

Publication number Publication date
US20210077471A1 (en) 2021-03-18
PH12022550610A1 (en) 2023-03-13
AU2020344214B2 (en) 2026-01-22
ES2982067T3 (es) 2024-10-14
EP4028000A1 (en) 2022-07-20
WO2021048610A1 (en) 2021-03-18
BR112022004672A2 (pt) 2022-06-07
US11351158B2 (en) 2022-06-07
PL4028001T3 (pl) 2024-07-22
HRP20240818T1 (hr) 2024-10-11
HUE066936T2 (hu) 2024-09-28
JP2025176113A (ja) 2025-12-03
JP2022551228A (ja) 2022-12-08
US12257241B2 (en) 2025-03-25
US11766425B2 (en) 2023-09-26
US20220184048A1 (en) 2022-06-16
MX2022003077A (es) 2022-07-11
RS65681B1 (sr) 2024-07-31
CN115052597A (zh) 2022-09-13
US20240041845A1 (en) 2024-02-08
EP4420673A3 (en) 2024-11-06
SMT202400250T1 (it) 2024-07-09
KR20220103698A (ko) 2022-07-22
US11207305B2 (en) 2021-12-28
CN114980889A (zh) 2022-08-30
AU2020347536A1 (en) 2022-04-14
US20230132691A1 (en) 2023-05-04
JP7804570B2 (ja) 2026-01-22
BR112022004645A2 (pt) 2022-06-21
CN120860031A (zh) 2025-10-31
AU2020344214A1 (en) 2022-04-21
CA3154129A1 (en) 2021-03-18
EP4028001B1 (en) 2024-04-10
CA3154317A1 (en) 2021-03-18
US11833139B2 (en) 2023-12-05
WO2021048611A1 (en) 2021-03-18
KR102991225B1 (ko) 2026-07-14
JP7769605B2 (ja) 2025-11-13
US20250281469A1 (en) 2025-09-11
US20210077472A1 (en) 2021-03-18
JP2026016690A (ja) 2026-02-03
CN115052597B (zh) 2025-07-08
EP4028001C0 (en) 2024-04-10
JP2022548252A (ja) 2022-11-17
EP4028001A1 (en) 2022-07-20
EP4420673A2 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
Aggarwal et al. Antibiotic resistance: a global crisis, problems and solutions
Estes et al. Present and future therapeutic strategies for melioidosis and glanders
Baucheron et al. TolC but not AcrB is essential for multidrug-resistant Salmonella enterica serotype Typhimurium colonization of chicks
US20250281469A1 (en) Rifabutin treatment methods, uses, and compositions
US11701346B2 (en) Rifabutin for the treatment of acinetobacter baumannii
US20160213626A1 (en) Methods for microbial biofilm destruction
Wang et al. Simultaneous functional disruption of the iron acquisition system and type VI secretion system results in complete suppression of virulence in Acinetobacter baumannii
Goessens et al. Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection
Choudhury et al. Importance of two Enterococcus faecium loci encoding Gls-like proteins for in vitro bile salts stress response and virulence
US10064860B2 (en) Pharmaceutical compositions containing clofazimine for inhibiting Clostridium difficile activity
HK40115867A (en) Rifabutin treatment methods, uses, and compositions
US11246905B2 (en) Treating infections using IdsD from Proteus mirabilis
US7595328B2 (en) Methods of use of quinolone compounds against pneumococcal and Haemophilus bacteria
WO2018160104A1 (ru) Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения
KR20230085439A (ko) 비결핵 항산균 감염 질환의 예방 또는 치료용 조성물
Castañeda-Meléndrez et al. Genomic characterization of a multidrug-resistant uropathogenic Escherichia coli and evaluation of Echeveria plant extracts as antibacterials
CN115089699B (zh) Apo-E模拟肽COG1410在制备抑制分枝杆菌药物中的应用
Rao et al. Targeting mycobacterial efflux system to enhance tuberculosis therapy
CN102138917A (zh) 二甲基黄青霉素在制备抗结核药物中的应用
CN121754530A (zh) 甘草素在制备杀菌剂或抗生素增效剂中的应用
EP1242079A1 (en) Methods of use of fluoroquinolone compounds againts bacteria
WO2024114572A1 (zh) 化合物在制备治疗或预防结核分枝杆菌感染的药物中的应用
Yrjänheikki Assay Setup for High Throughput Screening to Identify Novel Efflux Pump Inhibitors against Escherichia coli
WO2018070874A1 (en) Means and methods for reducing or avoiding antibiotic resistance and spread of virulence in human pathogens
Dzink‐Fox et al. Identification of Mar mutants among clinical bacterial isolates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)